Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis

Cotchett, Kelly R.; Dittel, Bonnie N.; Obeidat, Ahmed Z.

doi:10.1016/j.msard.2021.102787

Cited by 35 publications

(32 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…B cells have essential functions in regulating the immune response and may contribute to the pathogenesis of MS by regulating the T-cell activation process via antigen presentation, cytokine production, oligodendrocyte and neuronal injury contributing soluble toxic factors production, formation of ectopic germinal centers and providing a reservoir for Epstein-Bar virus infection in addition to producing antibodies [2]. Ofatumumab, a fully human anti-CD20 monoclonal antibody [3][4][5], depletes CD20 + B cells in the blood and lymphoid tissues through complement-dependent cytotoxicity and antibody-dependent cell-mediated cytotoxicity [6,7].…”

Section: Introductionmentioning

confidence: 99%

Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey

Ross¹,

Besser

Naval

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

Background Sensoready® autoinjector pen facilitates self-administration of subcutaneous ofatumumab injections at home. We aim to investigate patient and nurse preference for using Sensoready® versus comparator autoinjectors in multiple sclerosis (MS). Methods A pilot survey was conducted in Germany followed by in-field interviews across United States, Germany, France, and Italy. The survey recruited 80 MS patients and 50 MS nurses. Respondents were interviewed for 45-min on qualitative open-ended and quantitative close-ended survey consisting of 31 questions for patients and 41 for nurses. Ratings were measured on Likert scale from 1 (not at all important) to 10 (extremely important). Results “Easy to perform self-injection with the pen” and “Patient able to use independently” (both, mean overall score 9.4) were the most important attributes for both patients and nurses. Sensoready® scored high across most important attributes for both patients and nurses (p < 0.05). Sensoready® was preferred over comparator devices across majority of the important attributes (84%; p < 0.05), especially ease of use of the pen (mean overall score 9.4). Sensoready® was preferred over their current device by 9/10 nurses and 8/10 patients if they had to choose a treatment based on the device alone. Conclusion Both MS patients and nurses preferred the Sensoready® (ofatumumab) over comparator autoinjectors for their treatment, mostly driven by ease of administration.

show abstract

Section: Introductionmentioning

confidence: 99%

Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey

Ross¹,

Besser

Naval

et al. 2023

BMC Neurol

View full text Add to dashboard Cite

show abstract

“…It requires appropriate timing of the interval between stop and commencement of a new disease modifying treatment, taking into account pharmacokinetics and pharmacodynamics of natalizumab, in particular saturation of alpha4 integrin on lymphocytes, and the choice of a high-efficacy drug that can contain pathobiological and clinical MS activity with an acceptable safety profile. Based on the results of pivotal trials and real-world experience, the anti-CD20 monoclonal antibodies ocrelizumab and rituximab [13][14][15][16][17][18][19] and oral cladribine [20][21][22], a synthetic purine analogue, are accepted as highly efficacious and overall safe treatments for relapsing MS [13][14][15][16][17][18][19][20][21][22].…”

mentioning

confidence: 99%

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

et al. 2021

View full text Add to dashboard Cite

“…Ofatumumab induces greater CDC activity compared to ocrelizumab (77.1% vs. 7.1%) after a 2-hour exposure (57). In contrast, ADCC activity predominates over CDC activity in ocrelizumab and ublituximab (45,46,52). Compared with rituximab, ocrelizumab exhibits two-to five-fold greater ADCC activity and three-to five-fold lower CDC activity (58).…”

Section: Mechanisms Of Action Of Anti-cd20 Mabs: In Vitro Evidencementioning

confidence: 99%

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

et al. 2023

View full text Add to dashboard Cite

The immune system plays a significant role in multiple sclerosis. While MS was historically thought to be T cell-mediated, multiple pieces of evidence now support the view that B cells are essential players in multiple sclerosis pathogenic processes. High-efficacy disease-modifying therapies that target the immune system have emerged over the past two decades. Anti-CD20 monoclonal antibodies selectively deplete CD20+ B and CD20+ T cells and efficiently suppress inflammatory disease activity. These monotherapies prevent relapses, reduce new or active magnetic resonance imaging brain lesions, and lessen disability progression in patients with relapsing multiple sclerosis. Rituximab, ocrelizumab, and ofatumumab are currently used in clinical practice, while phase III clinical trials for ublituximab have been recently completed. In this review, we compare the four anti-CD20 antibodies in terms of their mechanisms of action, routes of administration, immunological targets, and pharmacokinetic properties. A deeper understanding of the individual properties of these molecules in relation to their efficacy and safety profiles is critical for their use in clinical practice.

show abstract

Comparison of the Efficacy and Safety of Anti-CD20 B Cells Depleting Drugs in Multiple Sclerosis

Cited by 35 publications

References 63 publications

Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey

Patient and nurse preference for Sensoready autoinjector pen versus other autoinjectors in multiple sclerosis: results from a pilot multicenter survey

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk

Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic

Contact Info

Product

Resources

About